Please try another search
Ziccum AB is a Sweden-based pharmaceutical company that is mainly engaged in developing vaccines. Ziccum develops new thermostable versions of vaccines and biologics for licensing to vaccine suppliers, developers, manufacturers and CDMOs in the global pharmaceutical industry. Ziccum's patented drying technology, LaminarPace, is unique. It can dry-formulate temperature-sensitive vaccine materials at room temperature with high yield and low waste. These robust, thermostable dry powders can be stored and transported worldwide without the need for a cold chain or freezing. The company conducts its business by entering into strategic collaborations with major pharmaceutical companies and offering licenses to the Company's patented technology.
Name | Age | Since | Title |
---|---|---|---|
Mikaela Bruhammar | 46 | 2019 | Independent Director |
Fredrik Sjovall | 42 | 2017 | Chairman |
Andreas Pettersson Rohman | 42 | 2021 | Director |
Per Gerde | 70 | 2023 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review